Interleukin-1 and Interleukin-6 Activities are Increased in the Cerebrospinal Fluid of Patients with CNS Lupus Erythematosus and Correlate with Local Late T-Cell Activation Markers

Abstract

We examined cerebrospinal fluid (CSF) samples from 12 patients with SLE and active central nervous system (CNS) involvement for their levels of the following cytokines: interleukin- 1 (IL-1) by means of two different assays-the IL-1 responsive murine cell line LBRM 33-1a5 and an ELISA for IL-1 alpha; IL-2 by means of the CTLL cell line responsive to it; and interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) both determined by a specific ELISA. We found that SLE CSF had significantly higher levels of IL-1 and IL-6 than did those obtained at surgery from eight controls without inflammatory neurologic disease. IL-2 and TNF were not detectable in any of the CSF samples. We also studied the status of activation in CSF T cells using monoclonal antibodies against early (anti-IL-2R (CD25) and antitransferrin (CD71)), late (anti-T10) and very late (anti-VLA-1) activation antigens, and found increased percentages of T10-bearing (18 ± 2 vs 3 ± 0.7%) and VLA-1-bearing T cells (12 ± 2 vs 0.7 ± 0.2%) in SLE patients as compared to controls (both P < 0.01). Levels of IL-1 and IL-6 correlated with T10 and those of IL-1 correlated also with VLA-1. Markers of early T-cell activation did not differ in SLE and control CSF. Because of these findings we analysed the effect of recombinant IL,-I, IL-6 or normal CSF on normal T cells and found that they did not induce the expression of activation markers. However, incubation in SLE CSF caused CD25, T10 and VLA-1 activation markers to become significantly expressed on cultured normal T cells. This expression of T10 and VLA-1 was partially inhibited by pre-incubation in anti-human IL-1 alpha polyvalent antibody.

Our findings suggest increased in situ production of IL- and IL-6 and perhaps other factors in CNS lupus that might condition T-cell activation in the CNS compartment. These findings could have pathogenetic significance.

Keywords

Interleukin-1 T-cell activation CNS lupus erythematosus CSF cytokines Interleukin-6 Tumor necrosis factor

Get full access to this article

View all access options for this article.

References

Keeffe EB , Bardana EJ , Harbeck RJ , Pirofsky B. , Carr RI Lupus meningitis. Antibody to deoxyribonucleic acid (DNA) and DNA:anti-DNA complexes in cerebrospinal fluid. Ann Int Med 1974; 80: 58-60.

Petz LD , Sharp GC , Cooper NR , Irvin WS Serum and cerebral spinal fluid complement and serum autoantibodies in systemic lupus erythematosus. Medicine 1971; 50: 259-75.

Hirano T. , Hashimoto H. , Shiokawa Y. et al. Antiglycolipid autoantibody detected in the sera from systemic lupus erythematosus patients. J Clin Invest 1980; 66: 1437-40.

Ellis SG , Verity MA Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977. Semin Arthritis Rheum 1979; 8: 212-21.

Bluestein HG , Pischel KD , Woods VL Immunopathogenesis of the neuropsychiatric manifestations of systemic lupus erythematosus. Springer Semin Immunopathol 1986; 9: 237-49.

Peress N. , Rouxburgh VA , Gelfand MC Binding sites for immune components in human choroid plexus. Arthritis Rheum 1981; 24: 520-6.

Vink A. , Uyttenhove C. , Wauters P. , Van Snick J. Accessory factors involved in murine T cell activation. Distinct roles of interleukin 6, interleukin 1 and tumor necrosis factor. Eur J Immunol 1990; 20: 1-6.

Mizel SB IL-I. Immunol Rev 1982; 63: 51-65.

Sironi M. , Breviario F. , Proserpio P. et al. IL-1 stimulates IL-6 production in endothelial cells. J Immunol 1989; 142: 549-53.

10.

Hirohata S. , Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33: 644-9.

11.

Tan EM , Cohen AS , Fries J. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.

12.

Hemler ME , Sánchez-Madrid F. , Flotte TJ et al. Glycoproteins of 210000 and 130000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines. J Immunol 1984 ; 132: 3011-8.

13.

Sanchez-Madrid F. , Krensky AM , Ware CF et al. Three distinct antigens associated with human T lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci USA 1982; 79: 7489-93.

14.

Sdnchez-Madrid F. , Toribio ML , Gambón F. , de Landázuri MO. Cell surface molecular changes on the activation of human thymocytes. J Immunol 1985; 135: 3938-43.

15.

Carrera AC , Sánchez-Madrid F. , López-Botet M. , Bernabeu C. , Ortiz de Landazuri M. Involvement of the CD4 molecule in a post-activation event on T cell proliferation . Eur J Immunot 1987; 17: 179-86.

16.

Malissen B. , Rabai N. , Liabeuf A. , Mawas C. Human cytotoxic T cell structures associated with expression of cytolysis.I. Analysis at the clonal cell level of the cytolysis-inhibiting effect of 7 monoclonal antibodies. Eur J Immunol 1982 ; 12: 739-47.

17.

Kearney JF , Radbruck A. , Liesegang B. , Rajewsky K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979; 123: 1550-68.

18.

Linker-Israeli M. , Bakke AC , Kifridou RC , Gendler S. , Gillis S. , Horwitz DA Defective production of interleukin-1 and interleukin-2 in patients with systemic lupus erythematosus. J Immunol 1983 ; 130: 2651-5.

19.

Alcocer-Varela J. , Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultivated lymphocytes from patients with SLE. J Clin Invest 1982; 69: 1388-92.

20.

Bresnihan B. , Oliver M. , Grigor G. , Hughes Grv. Brain-reactivity of lymphocytotoxic antibodies in systemic lupus erythematosus with and without cerebral involvement. Clin Exp Immunol 1977; 30: 333-7.

21.

Bluestein HG , Zvaifler NJ Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest 1976; 57: 509-16.

22.

Golombek SJ , Graus F. , Elkon KB Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 1090-7.

23.

Righi M. , Mori L. , De Libero G. et al. Monokine production by microglial cell clones. Eur J Immunol 1989; 19: 1443-8.

24.

Gijbels K. , Van Damme J , Proost P. , Put W. , Carton H. , Billiau A. Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 1990 ; 20: 233-5.

25.

Frei K. , Malipiero UV , Leist TP , Zinkernagel RM , Schwab ME , Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 1989 ; 19: 689-94.

26.

De Simoni MG , Sironi M. , De Luigi A. , Manfridi A. , Mantovani A. , Ghezzi P. Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6. J Exp Med 1990 ; 171: 1773-8.

27.

Crabtree GR Contingent genetic regulatory events in T lymphocyte activation. Science 1989; 243: 355-61.

28.

Pischel KD , Bluestein HG , Woods VW Jr. Very late activation antigens (VLA) are human leukocyte-neuronal crossreactive cell surface antigens. J Exp Med 1986; 164: 393-406.

29.

Terhorst C. , Van Agthoven A , Leclair K. , Snow P. , Reinherz E. , Schlossman S. Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell 1981; 23: 771-80.

30.

Gotlieb WH , Takacs L. , Young HA , Gusella L. , Durum SK Growth of immature (double negative) rat thymocytes in the presence of IL-1 . J Immunol 1990; 144: 2072-81.